A replicate study design for testing bioequivalence: A case study on two desmopressin nasal spray preparations

European Journal of Clinical Pharmacology

Volumn 59, Issue 8-9, 2003, Pages 631-636

  Joukhadar, Christian ^a   Schenk, Barbara ^a   Kaehler, Stefan T ^b   Kollenz, Christian J ^b   Bauer, Peter ^a   Müller, Markus ^a   Eichler, Hans Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Gebro Pharma GmbH   (Austria)

Author keywords

4 Period 2 sequence crossover study; Desmopressin; Human

Indexed keywords

DESMOPRESSIN; DESMOPRESSIN ACETATE;

ADULT; AEROSOL; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADMINISTRATION, INTRANASAL; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DEAMINO ARGININE VASOPRESSIN; HALF-LIFE; HUMANS; MALE; RENAL AGENTS; REPRODUCIBILITY OF RESULTS; THERAPEUTIC EQUIVALENCY;

EID: 0345598108     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0682-3     Document Type: Article

References (18)

1. Andersson KE, Arner B (1972) Effects of DDAVP, a synthetic analogue of vasopressin, in patients with cranial diabetes insipidus. Acta Med Scand 192:21-27
2. Becker DJ, Foley TP, Jr (1978) 1-Deamino-8-D-arginine vasopressin in the treatment of central diabetes insipidus in childhood. J Pediatr 92:1011-1015
3. Dimson SB (1977) Desmopressin as a treatment for enuresis. Lancet 1:1260
4. Pedersen PS, Hejl M, Kjoller SS (1985) Desamino-D-arginine vasopressin in childhood nocturnal enuresis. J Urol 133:65-66
5. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) D.D.A.V.P. in haemophilia. Lancet 2:1171-1172
6. Vilhardt H, Aberg M, Nilsson IM (1980) Possible use of DDAVP in coagulation disorders. In: Sutor AH, Schattauer FK (eds) DDAVP in bleeding disorders. Schattauer, Stuttgart, pp 36-41
7. Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O (1993) Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf) 38:177-182
8. Eller N, Kollenz CJ, Bauer P, Hitzenberger G (1998) The duration of antidiuretic response of two desmopressin nasal sprays. Int J Clin Pharmacol Ther 36:494-500
9. Eller N, Kollenz CJ, Hitzenberger G (1998) A comparative study of pharmacodynamics and bioavailability of 2 different desmopressin nasal sprays. Int J Clin Pharmacol Ther 36:139-145
10. O'Doherty DP, Bickerstaff DR, McCloskey EV, Atkins R, Hamdy NA, Kanis JA (1990) A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clin Sci (Lond) 78:215-219
11. Fiore CE, Romagnoli A, Foti R, Coppini A (1991) Assessment of the biological activity of synthetic salmon calcitonin by intranasal administration in healthy volunteers. Drugs Exp Clin Res 17:537-542
12. Combe B, Cohen C, Aubin F (1997) Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int 61:10-15
13. Christians U, First MR, Benet LZ (2000) Recommendations for bioequivalence testing of cyclosporine generics revisited. Ther Drug Monit 22:330-345
14. Lundin S, Vilhardt H (1986) Absorption of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in rabbits. Acta Endocrinol (Copenh) 112:457-460
15. Food and Drug Administration, Center for Drug Evaluation and Research, 1998b: Statistical methods for obtaining confidence intervals for individual and population bioequivalence criteria.http://www.fda.gov/cder/bioequivdata/ statproc.htm
16. Guidance for Industry - bioavailability and bioequivalence studies for orally administered drug products - general considerations.http://www.fda.gov/ cder/guidance/3615fnl.pdf, FDA/CDER (Oct 2001)
17. Note for guidance on the investigation of bioavailability and bioequivalence, CPMP/EWP/QWP/1401/98, EMEA (2001)
18. Chen ML, Lesko LJ (2001) Individual bioequivalence revisited. Clin Pharmacokinet 40:701-706